Some of the names on the move ahead of the open.» Read More
*MAGE-A3 fails to hit goal in Phase III lung cancer trial. March 20- An experimental cancer vaccine from GlaxoSmithKline has failed in a second test- this time against lung cancer- but the British company said it still hoped to identify a sub-group of patients in which it would work.
March 20- An experimental cancer vaccine from GlaxoSmithKline has failed in a second test- this time against lung cancer- but the British group said it still hoped to find a sub-group of patients in which it would work.
March 14- An experimental Amgen Inc cancer vaccine used to treat advanced melanoma, the deadliest form of skin cancer, proved effective in a late-stage study in shrinking tumors in a way that suggests the drug triggered the intended systemic immune response, according to data presented on Friday.
CNBC’s Jim Cramer says money should flow from stocks with heavy exposure to Ukraine and China into domestic retailers with strong growth.
New pill treatments show better cure rates and fewer side effects. Here are the companies behind those therapies.
Some of Tuesday's midday movers:
Some of Monday's midday movers:
U.S. bonds pushed higher on Friday, after disappointing manufacturing data from both the U.S. and China revived the safe haven bid for Treasurys.
Friday's midday movers:
U.S. stock prices could continue to correct, but it's too soon to say whether this is the big one.
CNBC's Jim Cramer offers some simple advice on how to deal with the Wall Street selloff.
U.S. stock index futures pointed to another steep loss on Friday, with European and Asian shares trading lower.
As Bristol-Myers Squibb prepares to report its Q4 earnings on Friday, CNBC's Morgan Brennan and Seamus Fernandez, Leerink Partners managing director & pharma analyst, discuss if now is the time to invest in the biotech.
With uncertainty rampant in the market, pros will be watching earnings very closely. Which results matter most to Cramer?
It’s time for the Lightning Round. Cramer makes the call on viewer favorites.
The "Fast Money" traders share their final trades of the day.
Some of Wednesday's midday movers:
Companies are making headlines before the bell Thursday.
AstraZeneca has agreed to buy Bristol-Myers Squibb's stake in the companies' diabetes joint venture in a deal worth $4.1 billion.
Cubist Pharmaceuticals is focused on treatments for fighting superbugs, an area many drug developers are avoiding. But its success may attract their attention.